Retour aux projets

17388.2 PFLS-LS

17388.2 PFLS-LS

Résumé

Design and Validation of new TLR agonists for therapeutic vaccination in oncology

Textes supplémentaires

Abstract

Modulating the cancer patient own immune system, to allow the specificdestruction of the tumoral cells, is becoming an attractive approach in oncology. This can be achieved through therapeutic cancer vaccines. One essential component to mount an efficacious anti-tumor immunity are adjuvants. Toll Like Receptor (TLR) agonists have risen recently as promising adjuvants of cancer vaccines. The goal of this project is to design and validate novel peptide agonist of TLR .

Participants

Madiha Derouazi

Wirtschaftspartner

madiha.derouazi@amaltherapeutics.com

Amal Therapeutics SA Madiha Derouazi Avenue de la Roseraie 64 1205 Genève GE CH

Vincent Zoete

Kontaktperson

Swiss Institute of Bioformatics (SI Vincent Zoete Bâtiment Genopode / Quartier Sorge 1015 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2014-12-31
Date de fin
2016-12-31
Coûts totaux approuvés
CHF 554750.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%